Your Dose of Cannabis Education
Your Dose of Cannabis Education
Only have a minute but want to Learn something every day™? Sign up to receive Your Dose of Cannabis Education, bringing featured content from our course library right to your inbox each day.
Your Dose of Cannabis Education is based on data from the studies and reviews published in the current peer-reviewed medical journals. Whether you are a healthcare provider, patient, caregiver, an individual working in the healthcare sector, or just a curious person, you can benefit from Your Dose of Cannabis Education.
Wake up every morning and get your dose of unbiased evidence-based cannabis education!
Alcohol's effects and CBD's effects on driving differ, according to Ashley Brooks-Russell, a public health professor at the University of Colorado who is running the federally funded driving simulator study that evaluates the effects of cannabis. "Alcohol and cannabis alter driving performance in different ways. Drunken drivers tend to speed, tailgate and act more aggressively than sober ones. Drivers who have used cannabis, on the other hand, tend to slow down, she said."Yes, a December 2024 in vivo study determined that CBD did exhibit antibacterial effects and did show antibiofilm activities within a specific concentration range.According to a secondary analysis from a cross-sectional survey involving patients with rheumatic conditions, cannabis was substituted for NSAIDS, opioids, sleep aids, muscle relaxants, benzodiazepines and gabapentin. The most common reasons given for substituting medical cannabis included: fewer side effects, better control of symptoms, and fewer adverse effects.Yes. A drug or other substance that causes changes in mood, awareness, thoughts, feelings, or behavior is considered to be psychoactive. Thus, CBD is also psychoactive, as it is anxiolytic, analgesic, and possibly antipsychotic. CBD is not euphorogenic, though. "The FDA grants Orphan Drug Designation to a drug intended to treat, prevent, or diagnose a rare disease or condition that affects fewer than 200,000 people in the US at the time of designation. The designation provides incentives, such as tax credits for qualified clinical trials, user fee exemptions, and the potential of seven years of market exclusivity after approval."
feed…New to TheAnswerPage? There’s lots we’d like to share with you and we don’t want you to miss a thing! Be sure to register today for “Your Dose of Cannabis Education” emails where you’ll gain valuable insights in small doses that fit your schedule and also be provided direct access to the archived daily content.